{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,4]],"date-time":"2026-03-04T16:16:55Z","timestamp":1772641015884,"version":"3.50.1"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,2,3]],"date-time":"2026-02-03T00:00:00Z","timestamp":1770076800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,3,4]],"date-time":"2026-03-04T00:00:00Z","timestamp":1772582400000},"content-version":"vor","delay-in-days":29,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Musculoskelet Disord"],"DOI":"10.1186\/s12891-026-09548-9","type":"journal-article","created":{"date-parts":[[2026,2,3]],"date-time":"2026-02-03T11:34:49Z","timestamp":1770118489000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Pharmacotherapy change patterns after fragility fracture in patients receiving bone-active medication: a fracture liaison service quality improvement cohort study"],"prefix":"10.1186","volume":"27","author":[{"given":"Hina","family":"Ansari","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alan","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rebeka","family":"Sujic","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Earl R.","family":"Bogoch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Victoria","family":"Elliot-Gibson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ravi","family":"Jain","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jennifer","family":"Weldon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Denise","family":"Linton","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joanna E.M.","family":"Sale","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,2,3]]},"reference":[{"issue":"2","key":"9548_CR1","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1007\/s00198-012-2090-y","volume":"24","author":"K Ganda","year":"2013","unstructured":"Ganda K, Puech M, Chen JS, et al. Models of care for the secondary prevention of osteoporotic fractures: a systematic review and meta-analysis. Osteoporos Int. 2013;24(2):393\u2013406.","journal-title":"Osteoporos Int"},{"issue":"1","key":"9548_CR2","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1007\/s11914-012-0130-3","volume":"11","author":"PJ Mitchell","year":"2013","unstructured":"Mitchell PJ. Best practices in secondary fracture prevention: fracture liaison services. Curr Osteoporos Rep. 2013;11(1):52\u201360.","journal-title":"Curr Osteoporos Rep"},{"key":"9548_CR3","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1016\/j.bone.2018.03.018","volume":"111","author":"CH Wu","year":"2018","unstructured":"Wu CH, Tu ST, Chang YF, et al. Fracture liaison services improve outcomes of patients with osteoporosis-related fractures: A systematic literature review and meta-analysis. Bone. 2018;111:92\u2013100.","journal-title":"Bone"},{"issue":"39","key":"9548_CR4","doi-asserted-by":"publisher","first-page":"E1333","DOI":"10.1503\/cmaj.221647","volume":"195","author":"SN Morin","year":"2023","unstructured":"Morin SN, Feldman S, Funnell L, et al. Clinical practice guideline for management of osteoporosis and fracture prevention in canada: 2023 update. CMAJ. 2023;195(39):E1333\u201348.","journal-title":"CMAJ"},{"issue":"17","key":"9548_CR5","doi-asserted-by":"publisher","first-page":"1864","DOI":"10.1503\/cmaj.100771","volume":"182","author":"A Papaioannou","year":"2010","unstructured":"Papaioannou A, Morin S, Cheung AM, et al. 2010 clinical practice guidelines for the diagnosis and management of osteoporosis in canada: summary. Can Med Assoc J. 2010;182(17):1864.","journal-title":"Can Med Assoc J"},{"issue":"4","key":"9548_CR6","doi-asserted-by":"publisher","first-page":"570","DOI":"10.1210\/er.2001-9002","volume":"23","author":"A Cranney","year":"2002","unstructured":"Cranney A, Guyatt G, Griffith L, Wells G, Tugwell P, Rosen C. Meta-analyses of therapies for postmenopausal osteoporosis. IX: summary of meta-analyses of therapies for postmenopausal osteoporosis. Endocr Rev. 2002;23(4):570\u20138.","journal-title":"Endocr Rev"},{"issue":"1","key":"9548_CR7","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1007\/s11657-019-0662-6","volume":"14","author":"S Singh","year":"2019","unstructured":"Singh S, Whitehurst DGT, Funnell L, et al. Breaking the cycle of recurrent fracture: implementing the first fracture liaison service (FLS) in British Columbia, Canada. Archives Osteoporos. 2019;14(1):116.","journal-title":"Archives Osteoporos"},{"issue":"12","key":"9548_CR8","doi-asserted-by":"publisher","first-page":"2114","DOI":"10.1002\/jbmr.3557","volume":"33","author":"SR Majumdar","year":"2018","unstructured":"Majumdar SR, McAlister FA, Johnson JA, et al. Comparing strategies targeting osteoporosis to prevent fractures after an upper extremity fracture (C-STOP trial): A randomized controlled trial. J Bone Miner Res. 2018;33(12):2114\u201321.","journal-title":"J Bone Miner Res"},{"issue":"3","key":"9548_CR9","doi-asserted-by":"publisher","first-page":"e12104","DOI":"10.5812\/ijem.12104","volume":"16","author":"AW Reynolds","year":"2018","unstructured":"Reynolds AW, Liu G, Kocis PT, Skowronski JN, Leslie DL, Fox EJ. Comparison of osteoporosis pharmacotherapy fracture rates: analysis of a MarketScan(\u00ae) claims database cohort. Int J Endocrinol Metab. 2018;16(3):e12104.","journal-title":"Int J Endocrinol Metab"},{"issue":"10117","key":"9548_CR10","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1016\/S0140-6736(17)32137-2","volume":"391","author":"DL Kendler","year":"2018","unstructured":"Kendler DL, Marin F, Zerbini CAF, et al. Effects of teriparatide and risedronate on new fractures in post-menopausal women with severe osteoporosis (VERO): a multicentre, double-blind, double-dummy, randomised controlled trial. Lancet. 2018;391(10117):230\u201340.","journal-title":"Lancet"},{"issue":"15","key":"9548_CR11","doi-asserted-by":"publisher","first-page":"1417","DOI":"10.1056\/NEJMoa1708322","volume":"377","author":"KG Saag","year":"2017","unstructured":"Saag KG, Petersen J, Brandi ML, et al. Romosozumab or alendronate for fracture prevention in women with osteoporosis. N Engl J Med. 2017;377(15):1417\u201327.","journal-title":"N Engl J Med"},{"issue":"5","key":"9548_CR12","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1016\/j.jogc.2021.09.013","volume":"44","author":"AA Khan","year":"2022","unstructured":"Khan AA, Alrob HA, Ali DS, Dandurand K, Wolfman W, Fortier M. Guideline No. 422\u00a0g: menopause and osteoporosis. J Obstet Gynecol Can. 2022;44(5):527\u2013e536525.","journal-title":"J Obstet Gynecol Can"},{"issue":"Suppl 3","key":"9548_CR13","doi-asserted-by":"publisher","first-page":"1","DOI":"10.4158\/EP.16.S3.1","volume":"16","author":"NB Watts","year":"2010","unstructured":"Watts NB, Bilezikian JP, Camacho PM, et al. American association of clinical endocrinologists medical guidelines for clinical practice for the diagnosis and treatment of postmenopausal osteoporosis. Endocr Pract. 2010;16(Suppl 3):1\u201337.","journal-title":"Endocr Pract"},{"issue":"1","key":"9548_CR14","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1007\/s11657-017-0324-5","volume":"12","author":"J Compston","year":"2017","unstructured":"Compston J, Cooper A, Cooper C, et al. UK clinical guideline for the prevention and treatment of osteoporosis. Arch Osteoporos. 2017;12(1):43.","journal-title":"Arch Osteoporos"},{"issue":"10","key":"9548_CR15","doi-asserted-by":"publisher","first-page":"2049","DOI":"10.1007\/s00198-021-05900-y","volume":"33","author":"MS LeBoff","year":"2022","unstructured":"LeBoff MS, Greenspan SL, Insogna KL, et al. The clinician\u2019s guide to prevention and treatment of osteoporosis. Osteoporos Int. 2022;33(10):2049\u2013102.","journal-title":"Osteoporos Int"},{"issue":"5","key":"9548_CR16","doi-asserted-by":"publisher","first-page":"1595","DOI":"10.1210\/jc.2019-00221","volume":"104","author":"R Eastell","year":"2019","unstructured":"Eastell R, Rosen CJ, Black DM, Cheung AM, Murad MH, Shoback D. Pharmacological management of osteoporosis in postmenopausal women: an endocrine Society* clinical practice guideline. J Clin Endocrinol Metab. 2019;104(5):1595\u2013622.","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"9548_CR17","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s00198-015-3334-4","volume":"27","author":"P Eiken","year":"2016","unstructured":"Eiken P, Vestergaard P. Treatment of osteoporosis after alendronate or risedronate. Osteoporos Int. 2016;27(1):1\u201312.","journal-title":"Osteoporos Int"},{"issue":"12","key":"9548_CR18","doi-asserted-by":"publisher","first-page":"2769","DOI":"10.1007\/s00198-012-2093-8","volume":"23","author":"A Diez-Perez","year":"2012","unstructured":"Diez-Perez A, Adachi JD, Agnusdei D, et al. Treatment failure in osteoporosis. Osteoporos Int. 2012;23(12):2769\u201374.","journal-title":"Osteoporos Int"},{"issue":"1","key":"9548_CR19","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1002\/jbmr.3039","volume":"32","author":"SR Cummings","year":"2017","unstructured":"Cummings SR, Cosman F, Lewiecki EM, et al. Goal-Directed treatment for osteoporosis: A progress report from the ASBMR-NOF working group on Goal-Directed treatment for osteoporosis. J Bone Min Res. 2017;32(1):3\u201310.","journal-title":"J Bone Min Res"},{"issue":"9","key":"9548_CR20","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1007\/s00198-004-1814-z","volume":"16","author":"SL Johnson","year":"2005","unstructured":"Johnson SL, Petkov VI, Williams MI, Via PS, Adler RA. Improving osteoporosis management in patients with fractures. Osteoporos Int. 2005;16(9):1079\u201385.","journal-title":"Osteoporos Int"},{"issue":"2","key":"9548_CR21","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1007\/s00198-003-1377-4","volume":"14","author":"G Hawker","year":"2003","unstructured":"Hawker G, Ridout R, Ricupero M, Jaglal S, Bogoch E. The impact of a simple fracture clinic intervention in improving the diagnosis and treatment of osteoporosis in fragility fracture patients. Osteoporos Int. 2003;14(2):171\u20138.","journal-title":"Osteoporos Int"},{"issue":"5","key":"9548_CR22","doi-asserted-by":"publisher","first-page":"366","DOI":"10.7326\/0003-4819-141-5-200409070-00011","volume":"141","author":"SR Majumdar","year":"2004","unstructured":"Majumdar SR, Rowe BH, Hanley DA, et al. A controlled trial to increase detection and treatment of osteoporosis in older patients with a wrist fracture. Ann Intern Med. 2004;141(5):366\u201373.","journal-title":"Ann Intern Med"},{"issue":"6","key":"9548_CR23","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1007\/s00198-005-0057-y","volume":"17","author":"M Che","year":"2006","unstructured":"Che M, Ettinger B, Liang J, Pressman AR, Johnston J. Outcomes of a disease-management program for patients with recent osteoporotic fracture. Osteoporos Int. 2006;17(6):847\u201354.","journal-title":"Osteoporos Int"},{"issue":"10","key":"9548_CR24","doi-asserted-by":"publisher","first-page":"1973","DOI":"10.2106\/JBJS.I.00878","volume":"92","author":"JE Sale","year":"2010","unstructured":"Sale JE, Beaton DE, Elliot-Gibson VI, Bogoch ER, Ingram J. A postfracture initiative to improve osteoporosis management in a community hospital in Ontario. J Bone Joint Surg Am. 2010;92(10):1973\u201380.","journal-title":"J Bone Joint Surg Am"},{"issue":"7","key":"9548_CR25","doi-asserted-by":"publisher","first-page":"2067","DOI":"10.1007\/s00198-011-1544-y","volume":"22","author":"JE Sale","year":"2011","unstructured":"Sale JE, Beaton D, Posen J, Elliot-Gibson V, Bogoch E. Systematic review on interventions to improve osteoporosis investigation and treatment in fragility fracture patients. Osteoporos Int. 2011;22(7):2067\u201382.","journal-title":"Osteoporos Int"},{"issue":"1","key":"9548_CR26","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1002\/jbmr.2023","volume":"29","author":"A D\u00edez-P\u00e9rez","year":"2014","unstructured":"D\u00edez-P\u00e9rez A, Adachi JD, Adami S, et al. Risk factors for treatment failure with antiosteoporosis medication: the global longitudinal study of osteoporosis in women (GLOW). J Bone Min Res. 2014;29(1):260\u20137.","journal-title":"J Bone Min Res"},{"issue":"3","key":"9548_CR27","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1007\/s00198-016-3794-1","volume":"28","author":"DE Beaton","year":"2017","unstructured":"Beaton DE, Vidmar M, Pitzul KB, et al. Addition of a fracture risk assessment to a coordinator\u2019s role improved treatment rates within 6 months of screening in a fragility fracture screening program. Osteoporos Int. 2017;28(3):863\u20139.","journal-title":"Osteoporos Int"},{"issue":"7","key":"9548_CR28","doi-asserted-by":"publisher","first-page":"1405","DOI":"10.1007\/s00198-020-05796-0","volume":"32","author":"JEM Sale","year":"2021","unstructured":"Sale JEM, Yang A, Elliot-Gibson V, et al. Patients 80\u2009+\u2009have similar medication initiation rates to those aged 50\u201379 in Ontario FLS. Osteoporos Int. 2021;32(7):1405\u201311.","journal-title":"Osteoporos Int"},{"issue":"8","key":"9548_CR29","doi-asserted-by":"publisher","first-page":"1671","DOI":"10.1007\/s00198-019-05017-3","volume":"30","author":"R Sujic","year":"2019","unstructured":"Sujic R, Beaton DE, Mamdani M, et al. Five-year refracture rates of a province-wide fracture liaison service. Osteoporos Int. 2019;30(8):1671\u20137.","journal-title":"Osteoporos Int"},{"issue":"6","key":"9548_CR30","doi-asserted-by":"publisher","first-page":"898","DOI":"10.1359\/JBMR.041231","volume":"20","author":"SB Jaglal","year":"2005","unstructured":"Jaglal SB, Weller I, Mamdani M, et al. Population trends in BMD testing, treatment, and hip and wrist fracture rates: are the hip fracture projections wrong? J Bone Miner Res. 2005;20(6):898\u2013905.","journal-title":"J Bone Miner Res"},{"key":"9548_CR31","unstructured":"Check Medication Coverage. https:\/\/www.ontario.ca\/page\/check-medication-coverage\/. Accessed June 13, 2022."},{"key":"9548_CR32","unstructured":"Formulary Search. https:\/\/www.formulary.health.gov.on.ca\/formulary\/. Accessed June 13, 2022."},{"issue":"1","key":"9548_CR33","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1007\/s11657-020-00796-3","volume":"15","author":"KK Clemens","year":"2020","unstructured":"Clemens KK, Jeyakumar N, Ou\u00e9draogo AM, Thain J, Khan T. Bisphosphonate and denosumab initiation in older adults in Ontario, canada: a population-based cohort study. Archives Osteoporos. 2020;15(1):133.","journal-title":"Archives Osteoporos"},{"issue":"4","key":"9548_CR34","first-page":"62","volume":"10","author":"J Kratzer","year":"2015","unstructured":"Kratzer J, Cheng L, Allin S, Law MR. The impact of private insurance coverage on prescription drug use in Ontario, Canada. Healthc Policy. 2015;10(4):62\u201374.","journal-title":"Healthc Policy"}],"container-title":["BMC Musculoskeletal Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12891-026-09548-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12891-026-09548-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12891-026-09548-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,4]],"date-time":"2026-03-04T11:01:06Z","timestamp":1772622066000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12891-026-09548-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,3]]},"references-count":34,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["9548"],"URL":"https:\/\/doi.org\/10.1186\/s12891-026-09548-9","relation":{},"ISSN":["1471-2474"],"issn-type":[{"value":"1471-2474","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,3]]},"assertion":[{"value":"4 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study is based on data collected through a quality improvement initiative. Approval for reporting of quality improvement data is not required by the Research Ethics Board at Unity Health Toronto. Approval for usage of these data was obtained from the data custodians, Osteoporosis Canada. This study adhered to the Declaration of Helsinki. Risk assessment was performed on the data, and all values under 5 were suppressed to maintain confidentiality.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"ERB reports an unrestricted research grant from Amgen Canada Inc.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"192"}}